Perform liver function test prior to treatment & periodically thereafter, monitor patients who develop increased transaminase levels until abnormalities resolve. Reduce dose or withdraw treatment if transaminase increase is >3 x ULN. May affect skeletal muscle & cause myalgia, myositis, myopathy that may progress to rhabdomyolysis. Patients w/ predisposing factors for rhabdomyolysis; measure CPK prior to treatment in patients w/ renal impairment, hypothyroidism, history of hereditary muscular disorder, toxicity w/ statin or fibrate, liver disease &/or substantial alcohol consumption & elderly >70 yr. Do not start treatment if CPK >5 x ULN. Discontinue use if creatinine phosphokinase (CPK) levels elevated to >10 x ULN or rhabdomyolysis is diagnosed or suspected. Concomitant use w/ ciclosporin, erythromycin, clarithromycin, itraconazole, ketoconazole, nefazodone, niacin, gemfibrozil, other fibric acid derivates or HIV-PIs may increase risk of rhabdomyolysis. Immune-mediated necrotizing myopathy (rarely). Galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption.